DiogenX
PrivateLast Round
Series A
Extension
Oct 31, 2023
Total Funding Raised
$45.05M
Company Overview
DiogenX operates in Healthcare & Life Sciences and is based in Marseille. Its latest recorded funding round was a Series A Extension round in October 2023.
DiogenX is a biotechnology company that develops innovative biologics and regenerative therapies for the treatment of type 1 diabetes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DiogenX Comparables
Compare DiogenX with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Betavive Ltd. | 85% | |
| Wink Biotherapeutics | 81% | |
| Caspian Therapeutics, Inc. | 81% |
For institutional investors. Book with your work email.
DiogenX Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Oct 31, 2023 | ||||
| Grant | Oct 1, 2023 | ||||
| Series A | May 10, 2023 | ||||
| Seed | Jun 16, 2020 |
For institutional investors. Book with your work email.
DiogenX Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant |
| Roche Venture Fund | Series A |
| Boehringer Ingelheim | Seed, Series A |
| Roche Venture Fund | Series A, Series A Extension |
| JDRF | Series A, Seed, Series A Extension |
| Boehringer Ingelheim Venture Fund | Seed, Series A, Series A Extension |
| Omnes Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2023
$2.65M grant from the European Innovation Council Fund
For institutional investors. Book with your work email.
DiogenX Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about DiogenX's valuation, stock price, and market status.
Is DiogenX a public or private company?
DiogenX is a private company.
What is the current stock price of DiogenX?
DiogenX is a private company, so its shares have no public market price. Caplight tracks DiogenX's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is DiogenX worth (valuation)?
Valuation information for DiogenX is not publicly available.
Can I buy DiogenX stock?
DiogenX shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was DiogenX's last funding round?
DiogenX's most recent funding round was Series A Extension on October 31, 2023.
Who are the main investors in DiogenX?
Key investors in DiogenX include Roche Venture Fund, Boehringer Ingelheim, Roche Venture Fund, Boehringer Ingelheim Venture Fund, AdBio partners.
Will DiogenX IPO soon?
No public IPO plans have been announced for DiogenX.
How can I track DiogenX secondary market activity?
Caplight tracks bids, offers, and trades in DiogenX's shares on secondary markets.